#USA #Denver #AMD #MingMed Biotechnology #QA102

MingMed Biotechnology's Breakthrough in AMD Treatment

MingMed Biotechnology Co., Ltd, a pioneering biomedical company, recently made a significant announcement regarding its oral drug QA102, designed to combat intermediate age-related macular degeneration (AMD). This announcement was made during the 2026 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Denver, Colorado. AMD, a chronic retinal disease, leads to progressive vision loss and affects millions globally, especially the elderly population.

The clinical trial, known as QA102-CS201, involved 150 participants diagnosed with intermediate atrophic AMD. The study was a randomized, double-blind, placebo-controlled trial where participants were assigned to receive either QA102 at doses of 200 mg or 400 mg twice daily or a placebo for up to 15 months. After a treatment period of 12 months, results showed a 59.2% reduction in the average volume of drusen (the yellow deposits that accumulate in the retina) in patients receiving the higher dose of QA102 compared to the placebo group.

Although the primary efficacy endpoint did not demonstrate a statistically significant difference between the QA102 and placebo groups, the overall findings remain encouraging. Specifically, the rate of growth of drusen volume was reduced by 118.2%, demonstrating significant potential for slowing the progression of AMD. Furthermore, the surface area of geographic atrophy, a severe form of AMD, showed a 42.7% reduction in the 400 mg group. This is a noteworthy finding, given the absence of current therapies that effectively slow the disease's progression.

Dr. Scott Whitcup, a leading expert in ophthalmic drug development, expressed optimism about these findings, stating that the intermediate stage of AMD is often overlooked in terms of treatment options. He noted the critical unmet medical needs for therapies that can either halt or mitigate the advancement of this disease.

Dr. Sunil Patel, one of the principal investigators, remarked, "The Phase II results for QA102 are very promising for the millions suffering from intermediate or advanced dry AMD. We expect this might pave the way for new treatment options in this field."

Fred Ouyang, PhD, the Chief Technology Officer of MingMed Biotechnology, emphasized the company's excitement in sharing their Phase II data with the global ophthalmological community. He highlighted QA102 as a first-in-class oral therapy for atrophic AMD, marking it as the first candidate to exhibit efficiency signals in treating intermediate AMD.

MingMed Biotechnology’s commitment to advancing treatment options for AMD reflects a broader trend in the industry where innovative therapies can transform patient outcomes. The company is poised to move QA102 into the next phase of clinical development, signaling hope for those affected by this debilitating condition.

As the prevalence of intermediate AMD continues to rise—affecting nearly 7% of individuals aged over 65 in the United States—the need for effective therapeutics has never been more crucial. The results from MingMed Biotechnology not only demonstrate the potential of QA102 but also signify an important step forward in the search for viable treatments that can alter the course of this sight-threatening disease.

About MingMed Biotechnology

MingMed Biotechnology is dedicated to developing cutting-edge treatments in various therapeutic areas, with a strong focus on ophthalmic health through its subsidiary, Smilebiotek Zhuhai Limited. The company's pipeline also includes other promising candidates like QA108, a traditional Chinese medicine aimed at addressing conditions such as advanced AMD. As research continues, MingMed remains at the forefront, championing innovations that enhance patients’ quality of life and preserve sight.